Insider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) Director Sells $82,125,000.00 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANXGet Free Report) Director Jay Lichter sold 1,500,000 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $54.75, for a total value of $82,125,000.00. Following the transaction, the director now owns 633,673 shares of the company’s stock, valued at $34,693,596.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Janux Therapeutics Trading Up 3.7 %

NASDAQ JANX opened at $44.16 on Friday. Janux Therapeutics, Inc. has a 1-year low of $5.65 and a 1-year high of $65.60. The company has a market capitalization of $2.29 billion, a price-to-earnings ratio of -36.20 and a beta of 3.71. The stock’s 50 day moving average is $48.45 and its two-hundred day moving average is $28.50.

Janux Therapeutics (NASDAQ:JANXGet Free Report) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.05. The business had revenue of $1.25 million for the quarter, compared to analyst estimates of $0.98 million. Janux Therapeutics had a negative return on equity of 13.49% and a negative net margin of 762.92%. On average, analysts predict that Janux Therapeutics, Inc. will post -1.34 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on JANX shares. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a research report on Tuesday, February 27th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $100.00 target price on shares of Janux Therapeutics in a research note on Thursday, May 9th. Wedbush boosted their price target on Janux Therapeutics from $53.00 to $74.00 and gave the company an “outperform” rating in a research note on Wednesday, May 8th. HC Wainwright upped their price target on Janux Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a report on Monday, May 13th. Finally, Jonestrading started coverage on Janux Therapeutics in a report on Tuesday, April 16th. They set a “buy” rating and a $70.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from, Janux Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $66.29.

View Our Latest Stock Report on Janux Therapeutics

Institutional Investors Weigh In On Janux Therapeutics

A number of hedge funds have recently made changes to their positions in JANX. Virtu Financial LLC bought a new stake in Janux Therapeutics during the first quarter worth about $609,000. Artal Group S.A. bought a new stake in Janux Therapeutics during the 1st quarter worth approximately $1,882,000. Janus Henderson Group PLC grew its position in Janux Therapeutics by 1.8% during the 1st quarter. Janus Henderson Group PLC now owns 1,965,546 shares of the company’s stock worth $73,961,000 after acquiring an additional 34,069 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in Janux Therapeutics during the 1st quarter valued at $739,000. Finally, Altitude Crest Partners Inc. bought a new position in Janux Therapeutics in the 1st quarter valued at $7,278,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

(Get Free Report)

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Further Reading

Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with's FREE daily email newsletter.